ABSTRACT
Description: Triacelluvax was a vaccine preparation against diphtheria, tetanus, and pertussis. It consists of diphtheria and tetanus toxoids, as well as three purified acellular pertussis antigens purified from cultures of a genetically engineered Bordetella pertussis strain. The product was formulated in a glass syringe as a suspension for injection. A single monodose preparation contained 30 IU diphtheria toxoid, 40 IU tetanus toxoid, 5 µg genetically modified pertussis toxin, 2.5 µg filamentous hemagglutinin (FHA) and 2.5 µg pertactin. The product was administered intramuscularly.
